Literature DB >> 6826223

Plasma and platelet vasopressin in essential hypertension and congestive heart failure.

J J Preibisz, J E Sealey, J H Laragh, R J Cody, B B Weksler.   

Abstract

In this study we found that, in 31 normal subjects, close to 90% of circulating arginine vasopressin (AVP), measured by radioimmunoassay, was associated with platelets. By using routine methods of centrifugation, which do not completely separate platelets, the normal range of plasma vasopressin was higher by twofold than the normal range in platelet-free plasma prepared by differential centrifugation, which was 1.4 +/- 1.0 sd pg/ml. Platelet vasopressin was 12.9 +/- 5.7 pg/ml. Patients with congestive heart failure had, on average, an elevated platelet-free plasma AVP, as did two patients with thrombocytopenia and one with thrombocytosis. Patients with essential hypertension had slightly high levels of platelet-free plasma AVP and demonstrated an abnormal inverse relationship between platelet-free plasma AVP and serum osmolality. Immunoreactive platelet vasopressin was slightly low in patients with essential hypertension and was subnormal in patients with congestive heart failure. These studies demonstrate that platelets normally present in centrifuged plasma cause an overestimation of the plasma vasopressin levels. Until the physiological meaning of plasma and platelet-bound AVP is understood, studies of circulating vasopressin should probably assess both plasma and platelet AVP levels.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6826223     DOI: 10.1161/01.hyp.5.2_pt_2.i129

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  37 in total

1.  Nature and properties of human platelet vasopressin receptors.

Authors:  D Vittet; A Rondot; B Cantau; J M Launay; C Chevillard
Journal:  Biochem J       Date:  1986-02-01       Impact factor: 3.857

Review 2.  Biomarkers in acute coronary artery disease.

Authors:  Matthias K Freynhofer; Miloš Tajsić; Johann Wojta; Kurt Huber
Journal:  Wien Med Wochenschr       Date:  2012-11-10

3.  Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33).

Authors:  W E Boertien; I J Riphagen; I Drion; A Alkhalaf; S J L Bakker; K H Groenier; J Struck; P E de Jong; H J G Bilo; N Kleefstra; R T Gansevoort
Journal:  Diabetologia       Date:  2013-04-28       Impact factor: 10.122

4.  Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study.

Authors:  Belen Ponte; Menno Pruijm; Daniel Ackermann; Philippe Vuistiner; Idris Guessous; Georg Ehret; Heba Alwan; Sonia Youhanna; Fred Paccaud; Markus Mohaupt; Antoinette Péchère-Bertschi; Bruno Vogt; Michel Burnier; Pierre-Yves Martin; Olivier Devuyst; Murielle Bochud
Journal:  J Am Soc Nephrol       Date:  2014-09-30       Impact factor: 10.121

Review 5.  Copeptin as a biomarker for prediction of prognosis of acute ischemic stroke and transient ischemic attack: a meta-analysis.

Authors:  Qian Xu; Yunfan Tian; Hao Peng; Hongmei Li
Journal:  Hypertens Res       Date:  2016-12-01       Impact factor: 3.872

6.  Response of novel biomarkers to BNP infusion in patients with decompensated heart failure: a multimarker paradigm.

Authors:  Wayne L Miller; Karen A Hartman; David O Hodge; Stacy Hartman; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Allan S Jaffe
Journal:  J Cardiovasc Transl Res       Date:  2009-08-14       Impact factor: 4.132

7.  Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.

Authors:  Debbie Zittema; Else van den Berg; Esther Meijer; Wendy E Boertien; Anneke C Muller Kobold; Casper F M Franssen; Paul E de Jong; Stephan J L Bakker; Gerjan Navis; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

8.  Cardiovascular and hormonal changes following haemorrhage in the anaesthetized Brattleboro rat with an extracorporeal circulation.

Authors:  F Hreash; J F Laycock
Journal:  Pflugers Arch       Date:  1990-09       Impact factor: 3.657

9.  Copeptin as a marker for arginine-vasopressin/antidiuretic hormone secretion in the diagnosis of paraneoplastic syndrome of inappropriate ADH secretion.

Authors:  A Wuttke; K C Dixit; G Szinnai; S C Werth; U Haagen; M Christ-Crain; N Morgenthaler; G Brabant
Journal:  Endocrine       Date:  2013-03-12       Impact factor: 3.633

10.  Serum copeptin as a new biomarker in the early diagnosis of decline in renal function of type 2 diabetes mellitus patients.

Authors:  Wen Hu; Yao-Jun Ni; Li Ma; Hai-Rong Hao; Liang Chen; Wei-Nan Yu
Journal:  Int J Clin Exp Med       Date:  2015-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.